Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PTC Therapeutics Inc (NASDAQ:PTCT)

12.79
Delayed Data
As of Dec 09
 -0.07 / -0.54%
Today’s Change
4.03
Today|||52-Week Range
35.40
-60.52%
Year-to-Date
PTC Therapeutics, Inc. in 3 Charts
Dec 07 / MotleyFool.com - Paid Partner Content
Why PTC Therapeutics, Inc. Stock Rose 75.4% in November
Dec 05 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close12.86
Today’s open12.90
Day’s range12.70 - 13.33
Volume709,776
Average volume (3 months)1,833,342
Market cap$438.9M
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)-70.71%
Earnings growth (this year)+12.72%
Earnings growth (next 5 years)--
Revenue growth (last year)+45.64%
P/E ratioNM
Price/Sales29.63
Price/Book1.92

Competitors

 Today’s
change
Today’s
% change
FLMLFlamel Technologies ...-0.02-0.19%
LBIOLion Biotechnologies...+0.40+6.06%
OMEROmeros Corp+0.05+0.50%
CTMXCytomX Therapeutics ...+0.07+0.57%
Data as of 4:00pm ET, 12/09/2016

Financials

Next reporting dateMarch 9, 2017
EPS forecast (this quarter)-$1.07
Annual revenue (last year)$36.8M
Annual profit (last year)-$170.4M
Net profit margin-463.60%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Class I Director
Stuart W. Peltz
Executive VP-Research, Operations &
Technology
Neil Gregory Almstead
Corporate headquarters
South Plainfield, New Jersey

Forecasts


Search for Jobs